These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 7633833)

  • 1. Mafosfamide enhances interleukin-2-generated human effector cell cytotoxic activity against K562 myeloid leukaemia cells.
    Hassan HT
    Med Oncol; 1994; 11(3-4):135-6. PubMed ID: 7633833
    [No Abstract]   [Full Text] [Related]  

  • 2. Enhancement of cytotoxic T lymphocyte growth from spleens of P815-tumor-bearing host mice with mafosfamide.
    Inge TH; Hoover SK; Frank JL; Kawabata TT; Bethke KP; Bear HD
    Cancer Immunol Immunother; 1992; 35(2):119-26. PubMed ID: 1534514
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Influence of low doses of an oxazaphosphorine on natural killer activity of human lymphocytes.
    Blomgren H
    Cancer Immunol Immunother; 1989; 29(2):151-3. PubMed ID: 2720708
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Heparin enhances generation of natural killer activity in vitro.
    Wasik M; Górski A
    Arch Immunol Ther Exp (Warsz); 1994; 42(1):73-6. PubMed ID: 7503640
    [TBL] [Abstract][Full Text] [Related]  

  • 5. ASTA-Z 7557 impairs human natural killer (NK) cell activity.
    Condiotti R; Slavin S; Nagler A
    Leuk Res; 1996 Feb; 20(2):169-74. PubMed ID: 8628016
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Agar capillary clonogenic microassays for cellular immunocytotoxic activities in human leukaemia and lymphoma.
    Maurer HR; Hassan HT
    Leuk Lymphoma; 1993 Mar; 9(4-5):305-13. PubMed ID: 7688626
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Successful adoptive immunotherapy of minimal residual disease after chemoradiotherapy and transplantation of bone marrow purged of leukaemia with mafosfamide.
    Skórski T; Kawalec M; Kawiak J
    Cancer Immunol Immunother; 1990; 32(1):71-4. PubMed ID: 2289201
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sensitivity of primary clonogenic blasts from acute lymphoblastic leukemia patients to an activated cyclophosphamide, viz., mafosfamide.
    Uckun FM; Chandan-Langlie M; Dockham PA; Aeppli D; Sladek NE
    Leuk Lymphoma; 1994 May; 13(5-6):417-28. PubMed ID: 8069187
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cyclophosphamide enhances anti-tumor effect of wild-type p53-specific CTL.
    Vierboom MP; Bos GM; Ooms M; Offringa R; Melief CJ
    Int J Cancer; 2000 Jul; 87(2):253-60. PubMed ID: 10861484
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Anti-tumor effect of human lymphocytes and interleukin-2.
    Anwer F; Mesri M; Rees RC; Kazmi SU
    J Pak Med Assoc; 1993 Mar; 43(3):45-9. PubMed ID: 8326667
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Potentiation of the antiblastic activity of mafosfamide by GM-CSF and interleukin-3: a possible use in the treatment of acute myeloblastic leukemia].
    Tolomeo M; Luparello M; Caravello E; Musso M; Abbadessa V; Perricone R; Cajozzo A
    Ann Ital Med Int; 1990; 5(4 Pt 1):341-7. PubMed ID: 2093359
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A comparison of the effects of ifosfamide vs. mafosfamide treatment on intracellular glutathione levels and immunological functions of immunocompetent lymphocyte subsets.
    Botzler C; Kis K; Issels R; Multhoff G
    Exp Hematol; 1997 Apr; 25(4):338-44. PubMed ID: 9131009
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cytotoxicity of cytokine-induced killer cells coated with bispecific antibody against acute myeloid leukemia cells.
    Kaneko T; Fusauch Y; Kakui Y; Okumura K; Mizoguchi H; Oshimi K
    Leuk Lymphoma; 1994 Jul; 14(3-4):219-29. PubMed ID: 7950910
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Chemoimmunotherapy of tumors: cyclophosphamide synergizes with exosome based vaccines.
    Taieb J; Chaput N; Schartz N; Roux S; Novault S; Ménard C; Ghiringhelli F; Terme M; Carpentier AF; Darrasse-Jèze G; Lemonnier F; Zitvogel L
    J Immunol; 2006 Mar; 176(5):2722-9. PubMed ID: 16493027
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Histamine dihydrochloride and interleukin-2 in the treatment of acute myeloid leukemia.
    Stadtmauer EA
    Semin Oncol; 2002 Jun; 29(3 Suppl 7):47-51. PubMed ID: 12068389
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Analysis of cytotoxic activity of the CD4+ T lymphocytes generated by local immunotherapy.
    Katsumoto Y; Monden T; Takeda T; Haba A; Ito Y; Wakasugi E; Wakasugi T; Sekimoto M; Kobayashi T; Shiozaki H; Shimano T; Monden M
    Br J Cancer; 1996 Jan; 73(1):110-6. PubMed ID: 8554971
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Oxazaphosphorines as biological response modifiers--experimental and clinical perspectives.
    Hilgard P; Pohl J; Stekar J; Voegeli R
    Cancer Treat Rev; 1985 Sep; 12(3):155-62. PubMed ID: 3907827
    [No Abstract]   [Full Text] [Related]  

  • 18. Targeting toll-like receptor 9 with CpG oligodeoxynucleotides enhances anti-tumor responses of peripheral blood mononuclear cells from human lung cancer patients.
    Ren T; Wen ZK; Liu ZM; Qian C; Liang YJ; Jin ML; Cai YY; Xu L
    Cancer Invest; 2008 Jun; 26(5):448-55. PubMed ID: 18568766
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Induction of "in vitro" apoptosis by fludarabine in freshly isolated B-chronic lymphocytic leukemia cells.
    Zinzani PL; Buzzi M; Farabegoli P; Tosi P; Fortuna A; Visani G; Martinelli G; Zaccaria A; Tura S
    Leuk Lymphoma; 1994 Mar; 13(1-2):95-7. PubMed ID: 8025527
    [TBL] [Abstract][Full Text] [Related]  

  • 20. PR1-specific cytotoxic T lymphocytes are relatively frequent in umbilical cord blood and can be effectively expanded to target myeloid leukemia.
    St John LS; Wan L; He H; Garber HR; Clise-Dwyer K; Alatrash G; Rezvani K; Shpall EJ; Bollard CM; Ma Q; Molldrem JJ
    Cytotherapy; 2016 Aug; 18(8):995-1001. PubMed ID: 27378343
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.